BridgeBio Pharma Inc
(NAS:BBIO)
$
29.08
-0.37 (-1.26%)
Market Cap: 5.50 Bil
Enterprise Value: 6.97 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 41/100 BridgeBio Pharma Inc at UBS Global Healthcare Conference Transcript
May 24, 2022 / 03:30PM GMT
Release Date Price:
$6.72
(-8.45%)
Operator
Thank you for standing by, and welcome to the UBS Health Conference
fireside chat with BridgeBio. (Operator Instructions) Please be advised that today's call may be recorded. I would now like to hand the call over to U.S. Biotechnology Analyst at UBS, Ellie Merle. Please go ahead.
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst
Thank you so much for joining us. I'm Ellie Merle, one of the biotech analyst here at UBS. Very happy to have BridgeBio with us here today. Presenting or joining us for a fireside chat from BridgeBio will be Neil Kumar, Founder and Chief Executive Officer. And with that, Neil, I'll pass it to you.
Questions & Answers
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst
Maybe just to kick off the discussion. It's been an eventful past 12 months for BridgeBio. Can you maybe frame the strategy and pipeline focus from here?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot